Reuters reports developing countries will be taking particular interest in the vaccine produced by China as they have limited early access to shots from Western drug makers.
Dong-yan Jin, a professor at the University of Hong Kong said: "China's approval could boost the credibility of the vaccine."But if the vaccine wants to take a share in the global market, especially in developed countries, more data is necessary."Health experts warn that if one vaccine is rolled out without enough evidence of its efficacy, then confidence in all of them could suffer as a result.The same Sinopharm shot announced by the United Arab Emirates on December 9 has a much higher 86% rate based on data which a spokeswoman declined to explain.Public health.